Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fuqiu Li

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Dermatitis : Contact, Atopic, Occupational, Drug|March 28, 2025
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
International Journal of Dermatology|November 22, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 15, 2023
Nail psoriasis in China: A prospective multicentre studyShiqi Wang, Jianjian Zhu, Ping Wang, et al.
Advances in Therapy|July 12, 2025
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
Clinical and Translational Allergy|November 19, 2025
Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
The Journal of Dermatological Treatment|July 6, 2026
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trialYan Zhao, Litao Zhang, Liming Wu, et al.
The British Journal of Dermatology|November 29, 2025
Ivarmacitinib ointment for the treatment of adults with mild-to-moderate atopic dermatitis: phase 3 part of a randomized, double-blind, placebo-controlled, phase 2/3 clinical trialDuoqin Wang, Jiyuan Wu, Qing Guo, et al.
Experimental Dermatology|June 19, 2026
Serum DSDNA is Associated With PsoriasisQi Zhen, Na Yin, Weiwei Chen, et al.
International Immunopharmacology|September 26, 2024
Serum dsDNA is environmentally contingentQi Zhen, Weiwei Chen, Yang Han, et al.
The Journal of Dermatological Treatment|July 15, 2026
Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trialsYan Zhao, Furen Zhang, Bin Yang, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Dermatitis : Contact, Atopic, Occupational, Drug|March 28, 2025
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
International Journal of Dermatology|November 22, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 15, 2023
Nail psoriasis in China: A prospective multicentre studyShiqi Wang, Jianjian Zhu, Ping Wang, et al.
Advances in Therapy|July 12, 2025
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
Clinical and Translational Allergy|November 19, 2025
Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
The Journal of Dermatological Treatment|July 6, 2026
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trialYan Zhao, Litao Zhang, Liming Wu, et al.
The British Journal of Dermatology|November 29, 2025
Ivarmacitinib ointment for the treatment of adults with mild-to-moderate atopic dermatitis: phase 3 part of a randomized, double-blind, placebo-controlled, phase 2/3 clinical trialDuoqin Wang, Jiyuan Wu, Qing Guo, et al.
Experimental Dermatology|June 19, 2026
Serum DSDNA is Associated With PsoriasisQi Zhen, Na Yin, Weiwei Chen, et al.
International Immunopharmacology|September 26, 2024
Serum dsDNA is environmentally contingentQi Zhen, Weiwei Chen, Yang Han, et al.
The Journal of Dermatological Treatment|July 15, 2026
Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trialsYan Zhao, Furen Zhang, Bin Yang, et al.
Pageof 6